| Recruitment of BRCA1 limits MYCN-driven accumulation of stalled RNA polymerase S Herold, J Kalb, G Büchel, CP Ade, A Baluapuri, J Xu, J Koster, D Solvie, ... Nature 567 (7749), 545-549, 2019 | 92 | 2019 |
| Association with Aurora-A controls N-MYC-dependent promoter escape and pause release of RNA polymerase II during the cell cycle G Büchel, A Carstensen, KY Mak, I Roeschert, E Leen, O Sumara, ... Cell reports 21 (12), 3483-3497, 2017 | 90 | 2017 |
| Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitro NCL Zembruski, G Büchel, L Jödicke, M Herzog, WE Haefeli, J Weiss Journal of antimicrobial chemotherapy 66 (4), 802-812, 2011 | 84 | 2011 |
| Combined inhibition of Aurora-A and ATR kinases results in regression of MYCN-amplified neuroblastoma I Roeschert, E Poon, AG Henssen, H Dorado Garcia, M Gatti, C Giansanti, ... Nature cancer 2 (3), 312-326, 2021 | 69 | 2021 |
| MiR-205-driven downregulation of cholesterol biosynthesis through SQLE-inhibition identifies therapeutic vulnerability in aggressive prostate cancer C Kalogirou, J Linxweiler, P Schmucker, MT Snaebjornsson, W Schmitz, ... Nature communications 12 (1), 5066, 2021 | 50 | 2021 |
| Next‐generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN‐amplified neuroblastoma A Schramm, J Köster, T Marschall, M Martin, M Schwermer, K Fielitz, ... International journal of cancer 132 (3), E106-E115, 2013 | 46 | 2013 |
| Drugging the “Undruggable” MYCN Oncogenic Transcription Factor: Overcoming Previous Obstacles to Impact Childhood Cancers AJ Wolpaw, R Bayliss, G Büchel, CV Dang, M Eilers, WC Gustafson, ... Cancer Research 81 (7), 1627-1632, 2021 | 40 | 2021 |
| Immune response modulation by Galectin-1 in a transgenic model of neuroblastoma G Büchel, JH Schulte, L Harrison, K Batzke, U Schüller, W Hansen, ... Oncoimmunology 5 (5), e1131378, 2016 | 22 | 2016 |
| LRP8‐mediated selenocysteine uptake is a targetable vulnerability in MYCN‐amplified neuroblastoma H Alborzinia, Z Chen, U Yildiz, FP Freitas, FCE Vogel, JP Varga, J Batani, ... EMBO Molecular Medicine 15 (8), e18014, 2023 | 18 | 2023 |
| TrkB-target galectin-1 impairs immune activation and radiation responses in neuroblastoma: implications for tumour therapy K Batzke, G Büchel, W Hansen, A Schramm International journal of molecular sciences 19 (3), 718, 2018 | 14 | 2018 |
| Selenocysteine metabolism is a targetable vulnerability in MYCN-amplified cancers H Alborzinia, Z Chen, U Yildiz, FP Freitas, FCE Vogel, J Varga, J Batani, ... bioRxiv, 2022.05. 17.492172, 2022 | 6 | 2022 |
| The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex D Papadopoulos, SA Ha, D Fleischhauer, L Uhl, TJ Russell, I Mikicic, ... Molecular Cell 84 (11), 2070-2086. e20, 2024 | 1 | 2024 |
| Association with TFIIIC limits MYCN localization in hubs of active promoters and chromatin accumulation of non-phosphorylated RNA Polymerase II R Vidal, E Leen, S Herold, M Müller, D Fleischhauer, C Schülein-Völk, ... bioRxiv, 2023.11. 18.567687, 2023 | 1 | 2023 |
| Direct RNA-binding by MYCN mediates feedback from RNA processing to transcription control D Papadopoulos, SA Ha, D Fleischhauer, L Uhl, K Schneider, I Mikicic, ... bioRxiv, 2023.08. 16.553474, 2023 | 1 | 2023 |
| Einfluss der Galectin-1 Expression auf die Tumor-Immun-Interaktion im Neuroblastom G Büchel Dissertation, Duisburg, Essen, Universität Duisburg-Essen, 2015, 2016 | 1 | 2016 |
| POTENTIAL OF NOVEL ANTIRETROVIRALS TO MODULATE EXPRESSION AND FUNCTION OF ABC-TRANSPORTERS: 59 N Zembruski, G Büchel, L Jödicke, W Haefeli, J Weiss British Journal of Clinical Pharmacology 68, 2009 | 1 | 2009 |
| Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy L Grunewald, L Andersch, K Helmsauer, S Schwiebert, A Klaus, ... bioRxiv, 2024.01. 27.576592, 2024 | | 2024 |
